Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Sobi (Swedish Orphan Biovitrum AB)
(https://synagis.com) 📸 Data Snapshot: June 19, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Sobi – Transforming the lives of people with rare diseases (https://synagis.com)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
REPEATED_BODY Sobi – Transforming the lives of people with rare diseases (https://synagis.com/middle-east/en/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
NAV_HEADING_REPEATED_BODY Sobi – Transforming the lives of people with rare diseases (https://synagis.com/en/pipeline/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Sobi – Transforming the lives of people with rare diseases (https://synagis.com/en/careers/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://synagis.com) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/middle-east/en/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/pipeline/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/careers/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /middle-east/en/ | 0 | 0 |
| /en/pipeline/ | 0 | 0 |
| /en/careers/ | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"additionalType": "MedicalOrganization",
"@id": "https://www.sobi.com/",
"description": "Sobi is an international biopharmaceutical company focused on rare diseases.",
"name": "Sobi",
"sameAs": [
"https://en.wikipedia.org/wiki/Swedish_Orphan_Biovitrum",
"https://www.linkedin.com/company/sobi/",
"https://www.youtube.com/c/Sobi-Pharma"
],
"url": "https://www.sobi.com/",
"telephone": "+4686972000",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+4686972000",
"email": "info@sobi.com",
"url": "https://www.sobi.com/",
"availableLanguage": [
"English",
"Swedish"
]
},
"image": {
"@type": "ImageObject",
"url": "https://www.sobi.com/sites/sobi/files/styles/banner/public/images/young-kid-leaves.jpg.webp?itok=DwHwUQ3X"
},
"logo": {
"@type": "ImageObject",
"representativeOfPage": "True",
"url": "https://www.sobi.com/themes/sobi/img/logo.svg",
"width": "284",
"height": "108"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "Box",
"addressLocality": "Stockholm",
"postalCode": "SE-112 76",
"addressCountry": "Sweden"
}
}
]
}
/middle-east/en/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"additionalType": "MedicalOrganization",
"@id": "https://www.sobi.com/",
"description": "Sobi is an international biopharmaceutical company focused on rare diseases.",
"name": "Sobi",
"sameAs": [
"https://en.wikipedia.org/wiki/Swedish_Orphan_Biovitrum",
"https://www.linkedin.com/company/sobi/",
"https://www.youtube.com/c/Sobi-Pharma"
],
"url": "https://www.sobi.com/",
"telephone": "+4686972000",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+4686972000",
"email": "info@sobi.com",
"url": "https://www.sobi.com/",
"availableLanguage": [
"English",
"Swedish"
]
},
"image": {
"@type": "ImageObject",
"url": "https://www.sobi.com/sites/sobi/files/styles/banner/public/images/young-kid-leaves.jpg.webp?itok=DwHwUQ3X"
},
"logo": {
"@type": "ImageObject",
"representativeOfPage": "True",
"url": "https://www.sobi.com/themes/sobi/img/logo.svg",
"width": "284",
"height": "108"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "Box",
"addressLocality": "Stockholm",
"postalCode": "SE-112 76",
"addressCountry": "Sweden"
}
}
]
}
/en/pipeline/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"additionalType": "MedicalOrganization",
"@id": "https://www.sobi.com/",
"description": "Sobi is an international biopharmaceutical company focused on rare diseases.",
"name": "Sobi",
"sameAs": [
"https://en.wikipedia.org/wiki/Swedish_Orphan_Biovitrum",
"https://www.linkedin.com/company/sobi/",
"https://www.youtube.com/c/Sobi-Pharma"
],
"url": "https://www.sobi.com/",
"telephone": "+4686972000",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+4686972000",
"email": "info@sobi.com",
"url": "https://www.sobi.com/",
"availableLanguage": [
"English",
"Swedish"
]
},
"image": {
"@type": "ImageObject",
"url": "https://www.sobi.com/sites/sobi/files/styles/banner/public/images/young-kid-leaves.jpg.webp?itok=DwHwUQ3X"
},
"logo": {
"@type": "ImageObject",
"representativeOfPage": "True",
"url": "https://www.sobi.com/themes/sobi/img/logo.svg",
"width": "284",
"height": "108"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "Box",
"addressLocality": "Stockholm",
"postalCode": "SE-112 76",
"addressCountry": "Sweden"
}
}
]
}
/en/careers/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"additionalType": "MedicalOrganization",
"@id": "https://www.sobi.com/",
"description": "Sobi is an international biopharmaceutical company focused on rare diseases.",
"name": "Sobi",
"sameAs": [
"https://en.wikipedia.org/wiki/Swedish_Orphan_Biovitrum",
"https://www.linkedin.com/company/sobi/",
"https://www.youtube.com/c/Sobi-Pharma"
],
"url": "https://www.sobi.com/",
"telephone": "+4686972000",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+4686972000",
"email": "info@sobi.com",
"url": "https://www.sobi.com/",
"availableLanguage": [
"English",
"Swedish"
]
},
"image": {
"@type": "ImageObject",
"url": "https://www.sobi.com/sites/sobi/files/styles/banner/public/images/young-kid-leaves.jpg.webp?itok=DwHwUQ3X"
},
"logo": {
"@type": "ImageObject",
"representativeOfPage": "True",
"url": "https://www.sobi.com/themes/sobi/img/logo.svg",
"width": "284",
"height": "108"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "Box",
"addressLocality": "Stockholm",
"postalCode": "SE-112 76",
"addressCountry": "Sweden"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Sobi (Swedish Orphan Biovitrum AB) (synagis.com)
https://synagis.com
📍 Industry: Medical Devices, Pharma & Biotech
27
BS / 100
Sobi presents as a legitimate, high-authority pharmaceutical entity with a very low BS profile. Its few points are deducted primarily for technical content repetition across sub-pages and the use of industry-standard aspirational power words in primary headers.
Info Density
Power-words vs. Substance ratio.
11
37% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
5
25% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
4
20% BS
Commodity Fingerprint
Detection of industry clichés/templates.
6
40% BS
Identity & Authority
Expert verifiability & Schema depth.
1
7% BS
1. Ensure the Pipeline sub-page delivers a unique, granular list of therapeutic assets instead of repeating the homepage. 2. Include direct outbound links to peer-reviewed publications within the ‘Our Science’ section. 3. Replace the generic H1 ‘We transform everyday life’ with a more specific value proposition citing the number of patients served or specific therapy areas. 4. Add Person schema for the Chief Medical Officer or lead researchers to bridge the remaining authority gap.
The content is perfectly aligned with the Pharma & Biotech industry, specifically focusing on rare diseases. Technical terminology such as ‘pegcetacoplan,’ ‘haematology,’ and references to the ‘EHA 2026’ conference confirm its specialized medical nature.
“The score of 27 is driven by Information Density (11 points) due to power word saturation in headings and Semantic Coherence (5 points) due to the identical content across the homepage and sub-pages in the crawl. The site's Trust and Authority scores are exceptionally strong, preventing a higher BS rating.”
Verified Analysis Date: June 19, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Sobi (Swedish Orphan Biovitrum AB), captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Sobi (Swedish Orphan Biovitrum AB): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://synagis.com to view the most current version of its content and learn from the source what this company is about and what it offers.